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Abstract
Background: Common genetic variants that regulate gene expression are widely suspected to contribute to the
etiology and phenotypic variability of complex diseases. Although high-throughput, microarray-based assays have
been developed to measure differences in mRNA expression among independent samples, these assays often lack
the sensitivity to detect rare mRNAs and the reproducibility to quantify small changes in mRNA expression. By
contrast, PCR-based allelic expression imbalance (AEI) assays, which use a “marker” single nucleotide polymorphism
(mSNP) in the mRNA to distinguish expression from pairs of genetic alleles in individual samples, have high sensitivity
and accuracy, allowing differences in mRNA expression greater than 1.2-fold to be quantified with high
reproducibility. In this paper, we describe the use of an efficient PCR/next-generation DNA sequencing-based assay
to analyze allele-specific differences in mRNA expression for candidate neuropsychiatric disorder genes in human
brain.
Results: Using our assay, we successfully analyzed AEI for 70 candidate neuropsychiatric disorder genes in 52
independent human brain samples. Among these genes, 62/70 (89%) showed AEI ratios greater than 1 ± 0.2 in at
least one sample and 8/70 (11%) showed no AEI. Arranging log2AEI ratios in increasing order from negative-to-
positive values revealed highly reproducible distributions of log2AEI ratios that are distinct for each gene/marker
SNP combination. Mathematical modeling suggests that these log2AEI distributions can provide important clues
concerning the number, location and contributions of cis-acting regulatory variants to mRNA expression.
Conclusions: We have developed a highly sensitive and reproducible method for quantifying AEI of mRNA
expressed in human brain. Importantly, this assay allowed quantification of differential mRNA expression for many
candidate disease genes entirely missed in previously published microarray-based studies of mRNA expression in
human brain. Given the ability of next-generation sequencing technology to generate large numbers of
independent sequencing reads, our method should be suitable for analyzing from 100- to 200-candidate genes in
100 samples in a single experiment. We believe that this is the appropriate scale for investigating variation in
mRNA expression for defined sets candidate disorder genes, allowing, for example, comprehensive coverage of
genes that function within biological pathways implicated in specific disorders. The combination of AEI
measurements and mathematical modeling described in this study can assist in identifying SNPs that correlate with
mRNA expression. Alleles of these SNPs (individually or as sets) that accurately predict high- or low-mRNA
expression should be useful as markers in genetic association studies aimed at linking candidate genes to specific
neuropsychiatric disorders.
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Neuropsychiatric disorders are complex diseases that are
strongly influenced by genetic, epigenetic, and environ-
mental factors [1]. One of the central challenges in current
psychiatric research is to determine the contributions of
these factors to major neuropsychiatric disorders and use
this knowledge to develop effective strategies for disease
diagnosis, treatment and prevention.
Beginning with the elucidation of a consensus DNA
sequence of the human genome and extending through
current efforts to exhaustively document genetic variability
in human populations, much has been learned about the
genes and genetic variants that contribute to major neu-
ropsychiatric disorders, such as schizophrenia [2,3],
Alzheimer’s disease [4,5] and drug addiction [6,7]. Unlike
Mendelian disorders, however, which can often be traced
to mutations that disrupt gene structure or coding
sequences, genetic markers that associate with complex
disorders often map to chromosomal sites located outside
of gene coding regions [8]. Such observations suggest that
genetic variants that regulate gene expression, rather than
disrupt gene structure, may be a major source of liability
for, or protection from, complex disorders [8,9].
Because of their potential importance for explaining
the etiology and phenotypic diversity of complex diseases,
there is currently great interest in developing methods
for identifying regulatory genetic variants [10,11]. Unlike
coding region mutations or chromosomal rearrange-
ments, which can be identified by DNA sequencing
alone, detection of regulatory variants requires experi-
mentation, such as measurements of variation in mRNA
expression or splicing. To meet this challenge, hybridiza-
tion-based microarray assays have been developed that
are capable of measuring variation in the expression of
hundreds-to-thousands of genes in multiple samples in a
single experiment [12,13].
While microarrays have provided important informa-
tion concerning variation in mRNA expression in a vari-
ety of tissues and cell lines and have the potential to
identify both cis-a n dtrans-acting regulatory variants
[14,15], they are not necessarily the best choice for ana-
lyzing mRNA expression in human brain. When used to
compare mRNA expression among independent samples,
microarray-based assays typically require large numbers
of samples to obtain statistically significant correlations
between genetic variants and mRNA expression and, in
the absence of a cDNA PCR amplification step, often
lack the sensitivity to detect rare mRNAs [16-18]. The
requirement for large numbers of samples to attain statis-
tical significance is closely related to the large variation in
mRNA expression among samples that is determined by
non-genetic factors. This is particularly a problem for
studies of mRNA expression in human brain, since the
quality of mRNA isolated from autopsy brain tissue often
varies among samples and the individuals that provided
the samples differ in ages, sex, medical history, drug use
and cause of death. Thus, variation in mRNA expression
caused by regulatory genetic variants is often obscured,
especially in small collections of unmatched samples.
In contrast to assays that involve comparisons between
independent samples, assays that measure allele-specific
differences in mRNA expression have the advantage that
the relative level of mRNA expression from each genetic
allele is determined within individual samples, with each
autosomal allele serving as a control for the other [19-21].
Combined with PCR-based-amplification of cDNA
reverse-transcribed from mRNA, this approach has pro-
duced highly accurate measurements of differential mRNA
expression in a variety of human tissues, including brain,
and provided important information about cis-acting
genetic variants that regulate mRNA expression [22-34].
To date, however, only assays of low-throughput design
have been used for allele-specific measurements of mRNA
expression in human brain.
In this paper we describe a medium-throughput method
for assaying allele-specific mRNA expression based on
PCR amplification and next-generation DNA sequencing
technology. Our results show that this assay produces alle-
lic expression imbalance (AEI) ratios (defined as the ratio
of the amount of mRNA derived from one genetic allele,
divided by the amount of mRNA derived from the other
allele) for mRNAs expressed in human brain of outstand-
ing quality and reproducibility.
After measuring AEI ratios for many candidate genes,
we noticed that graphs of log2AEI ratios ordered from
most-negative to most-positive produced distribution
patterns that are characteristic for each gene/marker
SNP pair. Mathematical modeling of these log2AEI dis-
tributions revealed that they can be a rich source of
information concerning the genetic variants that regu-
late mRNA expression for each gene. We believe that,
used together, our AEI assay and mathematical model-
ing provide powerful tools for identifying regulatory
genetic variants that contribute to major neuropsychia-
tric disorders.
Results
Next generation DNA sequencing-based AEI assay
An outline of our AEI assay is shown in Figure 1. Experi-
mental details are provided in Methods, Table 1, Addi-
tional file 1, Figures S1 - S6, and Additional file 2, Tables
S1 - S6. Briefly, genomic DNA (gDNA) isolated from
small (~30 mg) samples of frozen human brain was used
for both genotyping and as a control for cDNA-based
AEI measurements. To facilitate our long-term goal of
screening several-hundred neuropsychiatric disorder
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Page 2 of 19candidate genes, we carried out genomewide genotyping
for each of the 52 brains in our collection using Illumina
HumanOmni1-Quad microarrays. For most genes, this
information allowed us to infer the genotype of suitable
mRNA marker SNPs (mSNPs) for most of our candidate
genes. SNaPshot
® Multiplex kits (ABI) were used to gen-
otype mSNPs not included or tagged by SNPs on the Illu-
mina arrays.
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Figure 1 Flow diagram for AEI assays. Technical details are provided in Methods and Table 1 in the text and Additional file 1, Figures S1 - S5
and Additional file 2, Tables S1-S6.
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were used to amplify segments of gDNA or cDNA that
contain the corresponding mSNP. To reduce the total
number of PCR reactions, only gDNA and cDNA from
brain samples heterozygous for the mSNPs were used as
templates. To simplify the generation and analysis of the
PCR reaction products, PCR amplifications of individual
genes were carried out in sets, with each sample-primer
combination in an individual tube. In all, 74 sets (one
for each of the 74 candidate genes) comprising 3 to 36
gDNA template-based and 3 to 36 cDNA template-
based reaction mixes were independently amplified
(total: 2,762 reactions).
To ascertain the efficiency of the PCR amplifications,
aliquots from each reaction mix were resolved by elec-
trophoresis in 15% polyacrylamide gels, and the intensity
and purity of the PCR products examined by ethidium
bromide staining. Approximately 93% of the samples
yielded robustly stained, single PCR products. In cases
where staining of PCR products with the predicted
molecular weight was weak, additional PCR reactions
(~200) were carried out to increase the amount of PCR
products carried to the next step and to ensure that a
sufficient number of mRNA molecules were sampled to
obtain meaningful AEI ratios (see Methods for details).
Following confirmation of amplification, approximately
equal amounts of PCR products (one PCR product for
each gene with a heterozygous mSNP) derived from a
single brain sample were pooled, purified using QIAEXII
beads and ligated to an indexed Illumina adapter coding
for that sample (total: 52 gDNA template-derived sam-
ples + 52 cDNA template-derived samples). The ligated
PCR products from all of the brain samples were pooled
(total: one gDNA template-derived sample + one cDNA
template-derived sample) and resolved by electrophoresis
in 3% agarose gels. Ligation products in the appropriate
s i z er a n g e( 1 5 0-2 2 0b p )w e r ee x c i s e df r o mt h eg e l sa n d
used as templates for PCR amplification with Illumina
Primers 1.1 and 1.2 (see Additional file 1, Figure S1). The
resulting PCR products were sequenced using an Illu-
mina Genome Analyzer 2.0. T h ea b o v ep r o c e d u r e( w i t h
minor modifications) was independently carried out
twice (Illumina Assay-1 and Illumina Assay-2) for a sub-
set of genes and brain samples, beginning from the isola-
tion of gDNA and total RNA.
Following sequencing, reads were sorted, collated and
tabulated for calculation of AEI ratios using a custom
computer program, as described in Methods and Addi-
tional file 1, Figure S2. As shown in Additional file 1,
Figure S3, approximately 85% of the sequencing reads
were full-length (76 bp). Overall, approximately 60% of
the reads survived quality-control triage and were used
for the calculation of AEI ratios (Illumina Assay-2). In
total, we obtained approximately 6 × 10
6 useable, inde-
pendent reads for gDNA-derived sequences (1 flow cell
lane) and 7 × 10
6 reads for cDNA-derived sequences (2
lanes) in Assay-1 and 13.2 × 10
6 reads for gDNA-derived
sequences (2 lanes) and 18.5 × 10
6 reads for cDNA-
derived sequences (5 lanes) in Illumina Assay-2. For the
second assay, the number of reads/sample for individual
genes (i.e., the total reads for M + m alleles) ranged from
1,079 to 33,250 for gDNA-derived sequences (average =
9,911) and from 1,277 to 75,440 for cDNA-derived
sequences (average = 14,919) (data from Additional file 2,
Table S5).
An important application of gDNA-based AEI measure-
ments is the quantification of allele-specific bias that
occurs during the PCR-amplification of gDNA and cDNA
segments containing the marker SNP. As shown in Addi-
tional file 1, Figure S5, significant allele-specific amplifica-
tion bias for gDNA templates was observed for most
genes, with occasional genes showing greater than 1.5-fold
differences in amplification between alleles. This type of
bias has been previously observed in PCR-based AEI
assays [21,30,31].
One documented source of allele-specific PCR amplifi-
cation bias is the use of PCR primers that bind to sites
containing a SNP [35]. As listed in Additional file 2,
Table 1 Numerical summary for Illumina Assay-2
Stage gDNA/RNA Number
0 Candidate genes 74
0 Independent brain samples 52
0 Genotypes 52 × ~1.14 × 10
6
1 Isolated gDNA/cDNA 2 × 52 tubes
2 Individual PCR products 2762 tubes
2’ Supplemental PCR products ~200 tubes
3 Pooled, sample-specific PCR products 2 × 52 tubes
4 Sample-specific PCR products ligated to indexed Illumina adapters 2 × 52 tubes
5 Complete set of PCR products ligated to indexed Illumina adapters 2 × 1 tube
6 AEI Ratios 1,371 gDNA
1,313 cDNA
Xu et al. BMC Genomics 2011, 12:518
http://www.biomedcentral.com/1471-2164/12/518
Page 4 of 19Table S6, nine of our gene-specific PCR primers bind
DNA sequences containing nominal SNPs listed in the
NCBI SNP database. Three of these SNPs, however,
have 0 or very low heterozygosity in the Han Chinese
population and therefore should not present a problem.
One SNP has a heterozygosity of 0.162, but did not pro-
duce a significantly distorted log2AEI ratio. Among the
remaining five genes, all with SNPs of unknown hetero-
zygosity in the Chinese population, two showed signifi-
cant deviation of log2AEI values from 0.
In addition to PCR amplification bias, the presence of
pseudogenes, highly homologous genes or chromosomal
duplications (e.g. copy number variants) can also distort
genomic DNA AEI ratios. As described in Methods and
Additional file 3, we belatedly found evidence for off-target
sites in the human genome for the CYP2D6 and NTAN1
PCR primer sets. We found no evidence, however, for off-
target sites for any of the other PCR primer set used in
our study. Following previous examples [21,30,31], we
therefore corrected both gDNA and cDNA ratios by mul-
tiplying the AEI ratios by the inverse of the average
gDNA-based AEI for each gene. A list of the correction
factors used to normalize AEI ratios for each gene is pro-
vided in Additional file 2, Table S5.
In addition to providing a method for correcting AEI
measurements for PCR amplification bias, gDNA-based
AEI measurements also yield important information con-
cerning experimental error. Because only heterozygous
individuals were included in our final data sets, deviations
of normalized gDNA AEI ratios from 1 (or log2 normal-
ized ratios from 0) can be used to estimate this error. Two
different approaches were used to estimate experimental
error. In the first, we determined the distribution of nor-
malized gDNA AEI ratios for the entire set of measure-
ments and calculated the mean, standard deviation (SD)
and standard error of the mean (SEM) [details provided in
Additional file 3]. This analysis showed that 95% of the
normalized gDNA AEI ratios lay within the interval 0.82
to 1.22 (or ± 0.29 for log2 normalized gDNA AEI ratios).
As described in Additional file 3, this estimate of experi-
mental error was used to evaluate the presence or absence
of AEI for each gene in each sample.
In the second method, also described in Additional file
3, experimental error was estimated based upon a compar-
ison of deviations of log2AEI values from zero for normal-
ized gDNA AEI ratios as a function of the number of
sequencing reads used to calculate each ratio. As shown in
Additional file 1, Figure S6(a), deviations from log2AEI =
0, are greater than those predicted from a theoretical bino-
mial sampling error curve, but still relatively small and
decrease with increasing numbers of sequencing reads.
The legend of Additional file 1, Figure S6(b) describes an
empirical method for estimating the correlation between
the number of sampling reads and experimental error that
does not require assumptions about the statistical distribu-
tion of the error. As listed in Additional file 2, Table S4,
we estimate the log2 experimental error to be about ± 0.16
(i.e., linear AEI ratios between 0.895 and 1.117) for AEI
measurements generated by 1,000 reads, ± 0.10 (linear
ratios between 0.93 and 1.07) for AEI measurements gen-
erated by 13,500 reads and ± 0.09 (linear AEI ratios
between 0.94 and 1.064) for AEI measurements generated
by > 24,300 reads. As described below, this method for
evaluating experimental error was used in the mathemati-
cal modeling of log2AEI population distributions.
Log2AEI ratio distributions for 70 candidate
neuropsychiatric disorder genes
Figure 2 depicts representative results from our AEI
assays for the three candidate neuropsychiatric disorder
genes: (A) GAB2,( B )GNB1L and (C) DISC1.A ss h o w n
in the figure, each of these genes produces robust cDNA-
based log2AEI ratios (blue), that vary considerably in
extent and direction compared to gDNA-based controls
(red). To facilitate analysis, the samples are ordered from
low-log2AEI to high-log2AEI (left-to-right). When the
data is arranged in this fashion, it is apparent that each
gene displays a characteristic distribution of log2AEI
ratios. As explained below, these distributions often
reflect differences among the regulatory variants that
produce AEI with respect to: i) allele-frequencies, ii) rela-
tive contributions to log2AEI, and iii) degree of linkage to
the mSNP.
Figure 3 provides a graphical overview of our AEI mea-
surements for 70 genes. (Insufficient sequencing reads pre-
vented calculation of AEI ratios for 3 of the original 74
candidate genes, and, as explained above, CYP2D6 was
dropped due to co-amplification of CYP2D7a sequences.)
Parts (a), (b) and (c) of the figure provide a key for inter-
preting the diagram in part (d). Figure 3(a) shows the rela-
tionship between linear AEI ratios and log2AEI ratios. In
general, expressing AEI ratios in the log2 form has the
advantage that displacements of positive and negative
log2AEI ratios appear equal in magnitude, compared to
graphs of linear ratios, which compress negative displace-
ments. Figure 3(b and c) shows the color scheme for clas-
sifying log2AEI ratios as negative, non-significant or
positive. (The mSNP alleles in the numerator and denomi-
nator of each AEI ratio are listed in Additional file 2,
Table S1.) In this Figure, cDNA log2AEI ratios less than
-0.29 or greater than +0.29 (corresponding to linear ratios
less than 0.82 or greater than 1.22) were considered
significant.
As seen in Figure 3(d) there is considerable variability
in mRNA expression among the 70 candidate disorder
genes, with measured cDNA log2AEI ratios ranging
from -2.65 (CYFIP1) to +2.79 (NGFR), corresponding to
-6.27 and +6.9-fold differences in expression between
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Figure 2 Representative log2AEI distributions: GAB2, GNB1L and DISC1. Each pair of bars represents the gDNA-based (red) and cDNA-based
(blue) log2AEI ratios from a single sample. cDNA-based log2 AEI ratios are arranged in order from most- negative on the left to most-positive on
the right, forming a distinct distribution of log2AEI ratios for each gene. The selected genes illustrate three common patterns of log2AEI
population distributions: uniphasic, skewed and biphasic. As described in the text and in Additional file 4, log2AEI distributions often contain
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Page 7 of 19alleles, respectively. Figure 4 provides a summary of the
results from Illumina Assay-2. Surprisingly, 89% of our
candidate genes show significant log2AEI ratios for at
least one brain sample in our collection. Among samples
heterozygous for the mSNPs for a particular gene, the
proportion of samples with significant log2AEI ratios
ranged from 5% to 100%, with an average of 36% and
median 29%.
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Proportion of brain samples showing AEI for each gene
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Page 8 of 19Figure 5(a) shows that excellent agreement was
obtained for independent measurements of log2 AEI
ratios for GNB1L. Figure 5(b) summarizes the results of
comparisons of log2 AEI ratio measurements using our
PCR/DNA sequencing-based assay for 40 candidate
genes. More than eighty-percent (33/40) of these genes
yielded satisfactory-to-excellent coefficient of determina-
tion (r
2) values (> 0.7) when comparisons were analyzed
by linear regression analysis. For some genes, low r
2
values reflect the shape of their log2AEI distributions
(e.g., uniphasic, with a small range of log2AEI values) or
small sample number. Graphs showing the linear regres-
sion analysis of 12 representative genes are provided in
Additional file 1, Figure S7. To further validate the
results of our DNA sequencing-based assay, we indepen-
dently measured AEI ratios for several genes using a
PCR/primer-extension (SNaPshot
®)-based assay, which
has been extensively verified in previous studies
[20,30,31]. Figure 5(c) shows excellent agreement
between these two methods for GNB1L.
Modeling log2AEI distributions
As described above, log2AEI distributions are characteris-
tic for specific gene/mSNP pairs and highly reproducible.
To better understand these patterns, we developed a sim-
ple mathematical model that can mimic distributions of
log2AEI ratios with surprising accuracy. Modeling the
three candidate neuropsychiatric disorder genes GAB2,
GNB1L and DISC1 is briefly described in Additional file 4.
A comprehensive description of this model will be pre-
sented in a separate paper (Sun Y, et al, manuscript in
preparation).
According to our model, the shapes of log2AEI distribu-
tions are influenced by: i) the number of cis- and trans-
acting regulatory variants (rVar) [rVarA, rVarB, rVarC,
rVarT, etc.], ii) their major allele frequencies [P(A), P(B),
etc.] iii) the contribution of each variant to log2AEI ratios
[j, k, l, m, etc], iv) the degree of linkage disequilibrium
between rVar’s[ D ’(AB), etc.], v) the degree of linkage dise-
quilibrium between each rVar and the mSNP [D’(AM),
D’(BM), etc.] and vi) complex genetic, epigenetic or non-
genetic factors.
A comparison of the predicted and experimentally
determined log2AEI distributions for GAB2, GNB1L and
DISC1 i ss h o w ni nF i g u r e6 .I nt h ec a s eo fGAB2,t h e
observation that the log2AEI ratios are all in the same
(positive) direction suggests that mRNA expression is pri-
marily regulated by single cis-acting regulatory variant that
is in complete linkage disequilibrium with the mSNP. By
contrast, the skewed log2AEI distribution obtained for
GNB1L, in combination with a gradient in log2AEI values
and the presence of several samples with negative or non-
significant log2AEI ratios, suggests that mRNA expression
is regulated by two genetic variants, a cis-acting variant
partially linked to the mSNP and the other unlinked or
weakly linked to the mSNP. Finally, for DISC1, the nearly
equally balanced, biphasic AEI population distribution,
suggests the influence of multiple regulatory variants,
which are all unlinked (or very weakly linked) to the
mSNP. Details of the modeling of these genes are pre-
sented in Additional file 4 and a discussion of the results
with respect to previously published studies is presented
in Additional file 5.
Discussion
In this paper we describe a PCR/next-generation DNA
sequencing-based method for quantifying allele-specific dif-
ferences in mRNA expression and demonstrate that it pro-
duces detailed and highly reproducible information
concerning the expression of candidate neuropsychiatric
candidate genes in human brain. The two major strengths
of our assay are the ability to: 1) reproducibly measure
small differences in allelic expression for both common
and rare mRNAs and 2) generate population distributions
of log2AEI ratios that are useful for generating testable
hypotheses concerning the number, location and relative
contributions of genetic variants that regulate mRNA
expression.
When analyzing large numbers (50 - 200) of genes and
samples (50 - 100), the cost of our assay is approximately
one-half and hands-on time approximately one-third that
of low-throughput PCR/primer extension (SNaPshot
©)-
based assays. The use of DNA-sequencing instead of
SNaPShot
©-based primer-extension as the assay read-out
obviates the gene-by-gene fine-tuning often required for
SNaPshot assays, as well as the influences of differential
efficiencies of incorporation of fluorescently labeled
dideoxynuclotides into DNA and differences in the quan-
tum efficiency of the fluorophores, which can distort AEI
ratios. Experimental error in SNaPshot
©-based assays
varies among genes and generally only allows quantifica-
tion of AEI ratios greater than 1.2. By contrast, given suf-
ficient numbers of sequencing reads, AEI ratios as low as
1.1 can often be reliably measured using our method.
Our AEI assay also compares favorably to previously
developed high-throughput methods. Several studies have
described AEI assays that are based on differential hybridi-
zation in microarrays [36-39]. While each of these assays
is capable of detecting many thousands of differentially
expressed transcripts in a single experiment, two of the
studies [36,38] reported that reliable AEI could only be
detected for linear AEI ratios greater than 1.5. The other
two studies [37,39] described an assay that lacked a PCR
amplification step, potentially limiting the ability to use
the assay to measure AEI ratios for rare mRNA transcripts
in brain.
In addition to microarray-based assays, high-through-
put AEI assays based on PCR and second-generation
Xu et al. BMC Genomics 2011, 12:518
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Page 10 of 19DNA sequencing have also recently been described
[40-42]. Main BJ et al. [40] developed an AEI assay
similar in design to ours, which they successfully used
to analyze cis-a n dtrans-regulation of five Drosophila
simulans genes. Zhang K et al.[ 4 1 ]a n dL e eet al [42]
established a “digital RNA allotyping” assay, based on
deep sequencing of “padlock” oligonucleotide probes
designed to distinguish alleles of 27,000 exonic SNPs
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Page 11 of 19(minor allele frequency > 0.07). In this assay, genotyping
calls were based on a minimum of 20 sequencing reads
and AEI ratios for mRNAs expressed in human cells
were based on a minimum of 50 sequencing reads.
Several additional studies have used whole transcrip-
tome sequencing (RNA-seq) [43,44] strategies for geno-
mic-scale detection of AEI [45-49]. Although this
approach provides valuable information about the spec-
trum of mRNA in specific tissues, including information
concerning the expression of splicing variants, the depth
of coverage is usually not sufficient to obtain accurate
AEI ratios. Although several studies calculated AEI ratios
based on as few as 50 sequencing reads, Fontanillas et al.
[48], using 454 sequencing technology to quantify mRNA
expression in Drosophila,e s t a b l i s h e dt h a t5 0 0t o1 , 0 0 0
sequencing reads are required to accurately quantify AEI
ratios. This range is consistent with the results of our
analysis of experimental error as a function of sequencing
reads (Additional file 1, Figure S6 and Additional file 2,
Table S4).
To date, three major studies have used microarray-based
mRNA expression assays combined with genome-wide
genotyping to quantify mRNA expression and identify
eQTL’s for genes expressed in human brain [16-18].
Although each of these studies yielded important informa-
tion concerning mRNAs that could be detected, each also
lacked the sensitivity to detect mRNAs for many impor-
tant candidate disease genes.
Myers et al. [16] used the Illumina HumanRefseq-8
Expression BeadChip system to quantify levels of 14,078
transcripts in RNA isolated from 193 independent sam-
ples of human cortex. Screening SNPs located within
approximately 2.1 M bp chromosomal segments centered
on each gene for correlations between genotype (additive
model) with mRNA expression yielded significant asso-
ciations for 433 SNP-transcript pairs (in 99 transcripts =
0.7% of detected mRNA transcripts), with the majority of
the associated SNPs located within 70 kb of the tran-
script. Although each of these cis-associations was signifi-
cant after correction for SNPs tested in the same region,
only two genes, KIF1B and IPP, remained significant after
corrections for multiple testing for all SNPs-transcript
pairs that were studied. Furthermore, with the exception
of MAPT [26], no genes previously demonstrated to exhi-
bit AEI in human cerebral cortex in PCR-based AEI
assays, including DTNBP1 [22], COMT [23], GNB1L [50],
TBX1 [50], OPRM1 [28], DRD2 [29], and CHRNA5 [33]
were included in the list of nominally significant cis SNP-
transcript pairs.
I naf o l l o w - u ps t u d yb yt h es a m eg r o u p ,W e b s t e ret al
[17] used more stringent inclusion procedures for
expressed transcripts, analyzing 8650 transcripts in 486
late-onset Alzheimer’s disease (LOAD) cases and 279
control brain samples. Again, none of the AEI-positive
genes listed above was correlated with a SNP located in
the region of the gene, although a SNP located on chro-
mosome 1 was weakly correlated with expression of
GNB1L mRNA in the set of AD brain samples (r
2 =t h e
contribution of SNP rs7527404 to the variance of tran-
script expression = 0.13).
Using expression data from 269 brain samples available
on the Stanley Medical Research Institute Online Geno-
mics database (https://www.stanleygenomics.org), in-
house genotyping on Affymetrix Human Genome U133A
microarrays, and careful pre-screening of the of the
expression and genotyping data to eliminate the effects of
confounding variables, Liu et al., [18] identified 903 SNP-
expression probeset pairs (in 826 genes) that showed sig-
nificant “region-wide” association (i.e., significant after cor-
rection for multiple testing of SNPs in the region of the
gene for correlations between genotype and expression).
Among these, 562 SNP-expression probeset pairs (in 106
genes) also showed significant “phenotype-wide” associa-
tion (i.e., significant after correction for multiple testing
for all genotype-expression correlations examined).
Although the study of Liu et al., identified more genes
that are regulated by cis-acting genetic elements com-
pared to the study of Myers et al., with the exceptions of
GSTM3 [51] (significant at both the “region-wide” and
“phenotype-wide” levels) and COMT [23] (significant at
the “region-wide,” but not the “phenotype-wide” level),
genes previously shown in PCR-based assays to have sig-
nificant AEI in human cortex were not detected. As
noted by the authors, the microarray-based expression
assays also did not detect mRNA levels sufficient for ana-
lysis for many additional neuropsychiatric disorder candi-
date genes.
Among the 70 genes examined in the present study,
MAPT was reported by Myers et al.[ 1 6 ]t oh a v es i g n i f i -
cant P-values, but the remaining 69 were not detected. In
addition to GNB1L, Webster et al. [17] reported correla-
tions between transcript levels and trans-SNPs for an
additional three of our candidate genes, CLU, NPY and
PICALM, but no correlating cis-SNPs. In the study of Liu
et al [18], four of our candidate genes, HTR2A, LRP1,
NTAN1 and GRIA2, attained significant “region-wide”
P-values, but not “phenotype-wide” P-values, 23 genes
were not significant at either level, and 44 were not
detected at levels sufficient for analysis.
Taken together, the results of these three studies
strongly suggest that PCR-based mRNA expression assays
will prove to be the method of choice for investigating
genetic regulation of many important disease candidate
genes in human brain. An important limitation of this
method that should be mentioned, however, is that some
candidate genes lack suitable mSNPs for AEI measure-
ments or contain only mSNPs with very low heterozygos-
ity. For such genes, the traditional approach of looking for
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sured by real-time PRC) genotypes of candidate regulatory
SNPs is the next-best option.
By contrast to previously published studies, our study
s u f f e r ss o m e w h a tf r o ma n“embarrassment of riches” in
that a very large percentage of our genes showed differen-
tial mRNA expression among the samples tested. For
example, previous genome-wide studies of eQTL’sa n d
allele-specific expression (mostly in cell lines for trans-
formed human lymphocytes) yielded estimates for differ-
entially regulated genes in the range of 10 - 54% [52,53].
By contrast, studies focusing on sets of candidate disease
genes, have consistently detected higher percentages of
genes showing AEI: greater than 50% [20,22,54]. The
observation that candidate genes are enriched for genes
that show allele-specific differences in mRNA expression
is consistent with the hypothesis that variation in gene
expression contributes to susceptibility to complex dis-
eases [10]. Consistent with this idea, a recent study
showed that putative schizophrenia susceptibility alleles
are enriched for alleles that influence mRNA expression in
human brain [55].
In addition to focusing on leading candidate genes for
schizophrenia, Alzheimer’s disease and drug addition,
another reason for the high percentage of genes showing
AEI in our study is the accuracy of our assay, which
allows small deviations from 1.0 to be detected with con-
fidence. If experimental error based on sequencing read
number is taken as the sole standard, our assay reliably
detects AEI ratios was small as 1 ± 0.1. Taking ± 0.1 as
the cut-off, almost all of our 70 candidate genes show
AEI in at least one sample. These observations suggest
that small allele-specific deviations from 1.0 are nearly
ubiquitous and raise the question concerning when
allele-specific differences in mRNA expression become
biologically meaningful.
Certainly the existence of AEI is not equally important
for all genes. Rather, biologically important AEI is likely
to be restricted to genes that encode proteins that are
limiting for important biological processes. An example
of such a gene is TPH2, which encodes tryptophan
hydroxylase-2, the rate-limiting enzyme in the synthesis
of serotonin in the brain [56]. For such “dose-sensitive”
genes, even small changes in mRNA expression may have
a significant biological effect, if the changes in mRNA are
reflected in changes in protein level and/or enzymatic
activity.
A good example of a dose-sensitive gene that does not
encode an enzyme is APP, encoding amyloid precursor
protein, the precursor of the toxic peptide Ab, which accu-
mulates in the brains of patients with Alzheimer’s disease
(AD) [57]. Duplication of the APP gene, as the result of
rare chromosomal duplications or, as in the case of
Down’s syndrome, duplication of the entire chromosome
21, is strongly associated with early-onset AD [58]. Rare
promoter mutations that modestly increase APP expres-
sion are also linked to early-onset AD [59]. If duplication
of APP, which may increase mRNA expression by 50%,
can have a dramatic effect on the risk and age of onset of
AD, it is not unlikely that smaller increases in mRNA
expression, e.g., 10% - 40%, contribute to the more com-
mon late-onset AD (LOAD). The same argument holds
for genes encoding enzymes and other proteins that func-
tion in the production, degradation, clearance and deposi-
tion of Ab. Clearly analysis of as many genes as possible in
these pathways and estimating their combined effects will
be important to assessing the relative susceptibility to AD.
We believe that our assay provides the optimal balance
between throughput and sensitivity that will be useful for
investigating sets of genes that function within specific
biological pathways implicated in AD and other neuropsy-
chiatric disorders.
One of the major implications our AEI measurements
and mathematical modeling is that, for many genes,
mRNA expression is a “complex phenotype,” involving 2,
3o rm o r ecis-acting regulatory variants (or, in some cases,
at least one cis-acting variant plus additional trans-acting
variants). These results are consistent with detailed studies
showing that specific genes are regulated by multiple cis-
and trans-acting variants [60-62]. Based upon our model-
ing, at least two cis-acting regulatory variants are required
to account for the observed spectrum of GNB1L log2AEI
ratios in our brain samples. This implies that predicting
high- and low-expression mRNA will require the identifi-
cation of two variants, or, alternatively, two “indicator” (i)
SNPs that are tightly linked to these variants and accu-
rately predict high- and low-mRNA expression. Haplo-
types comprised of high- or low-expression alleles of
regulatory variants or iSNPs would provide the best
genetic markers to test the hypothesis that differential
expression of GNB1L contributes to risk of developing
schizophrenia. One of the major goals of our AEI studies
is to identify the best possible genetic markers for associa-
tion studies for this and other candidate neuropsychiatric
disorder genes.
In summary, we believe that the AEI assay and molecu-
lar modeling described in this study will provide useful
tools for investigating the genetic basis of complex dis-
eases, including major neuropsychiatric disorders. These
methods should be immediately useful for investigating, in
a comprehensive manner, the possible contributions of
genes that function within specific biological pathways and
systems that contribute to disease. They should also be
useful for comparing the regulation of specific genes in
developing and mature brain [55], investigating region-
and cell-type specific mRNA expression [63], integrating
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and investigating epigenetic mechanisms of gene regula-
tion [66,67].
Conclusions
In this study we describe a novel, PCR and next-genera-
tion DNA sequencing-based method for quantifying allelic
expression imbalance (AEI) of mRNA expression in
human brain. We show that this assay produced detailed
and highly reproducible measurements of AEI ratios for
70 neuropsychiatric disease candidate genes. We also
demonstrate that population distributions of log2-trans-
formed AEI ratios for individual gene/marker SNP pairs
can provide important information concerning the num-
ber, location and effect size of regulatory variants that
influence mRNA expression. Taken together, our assay
and mathematical modeling provide powerful tools for
analyzing the genetic regulation of candidate disease genes
and should be useful for investigating how regulatory
genetic variants contribute to complex human disorders.
Methods
Selection of Candidate genes and marker (m)SNPs
Candidate genes for this study were selected based on
their relevance to neuropsychiatric disorders currently
under investigation in the Saffen laboratory: i) schizophre-
nia/autism, ii) Alzheimer’s disease and/or iii) heroin addic-
tion. Particular attention was given to genes that had been
previously linked to one or more of these disorders in
genetic association studies or are located within copy
number variations (CNVs) that associate with schizophre-
nia and/or autism. To allow allele-specific quantification
of mRNA expression, candidate genes mRNAs were
required to contain at least one single nucleotide poly-
morphism (SNP) with high heterozygosity in the Han Chi-
nese population for use as a marker SNP. Most of the
selected candidate genes had not previously been tested
for allelic expression imbalance (AEI) in human brain,
although several previously studied genes were included
for the purpose of comparison and verification. A list of
the 74 genes included in this study can be found in Addi-
tional file 2, Table S1.
Human Brain tissue
Frozen sections of human brain from: i) prefrontal cortex
(Brodmann Area 46), ii) hippocampus, iii) amygdala, iv)
ventral striatum/nucleus accumbens, v) substantia nigra,
and vi) rostral pons from 52 Han Chinese individuals were
obtained from the Chinese Brain Bank Center (South-
Central University for Nationalities, Wuhan, China). This
sample population comprised 25 males and 27 females
(ages: 1 to 70; average 41) and cause of death, included ill-
ness, traffic accidents, electronic shock and heart-attacks.
Postmortem intervals were less than 36 hours (most less
than 24 hours). In all cases, written consent for tissue
donation was obtained from relatives (on file at CBBC).
Use of human autopsy tissue is considered non human-
subject research and is IRB exempt under NIH guidelines.
Isolation of genomic DNA and total RNA
Frozen brain tissue (~ 30 mg) was homogenized in 180 μl
of DNA lysis buffer + 20 μl proteinase K (QIAamp
®DNA
Mini kit, Qiagen) and genomic DNA (gDNA) isolated,
according to the instructions of the manufacturer (Qiagen,
Valencia, CA, USA). For total RNA, frozen brain tissue
(~ 100 mg) was homogenized in (1 ml) Trizol reagent
(Invitrogen, Carlsbad, CA, USA), and total RNA isolated
as recommended by the manufacturer. Following resupen-
sion in 30 μl RNAase-free water containing 2 μlR N a s e -
OUT™ (Invitrogen), contaminating genomic DNA was
eliminated by incubating at 37°C in the presence of 30 U
RNase-free DNase I (New England Biolabs) for 30 min.
The RNA was then purified using Qiagen RNeasy Mini
kits, as recommended by the manufacturer, resuspended
in 30 μl RNAase-free water and stored at -80°C. The quan-
tity of gDNA and total RNA was determined using a
Nanodrop spectrophotometer (Thermo Inc). [Note: incu-
bation of total RNA with large quantities of DNase I was
required to prevent amplification of small genomic DNA
sequences during PCR-amplifications using cDNA
templates.]
Genotyping
Genomewide genotyping was carried out using Huma-
nOmni1-Quad genotype arrays (Illumina) for each of the
52 independent samples in our study (~ 1.14 × 10
6 geno-
types/sample). For SNPs not included in these arrays,
additional genotyping was carried out using SNaPshot
®
Multiplex kits (Applied Biosystems), as previously
described [30,31]. Gene-specific PCR primers were
designed using Oligo 6.0 (National Biosciences Inc., Ply-
mouth, MN, USA) and synthesized by Sangon Biotech
(Shanghai, China). For most genes, the same pairs of PCR
primers (forward and reverse) were used for genotyping
and amplification of cDNA sequences. Sequences of these
primers are listed in Additional file 2, Table S2. In cases
where forward and reverse PCR primers designed for
amplifying cDNA sequences are located on different
exons, alternative primer sets were used for genotyping
and for measuring gDNA AEI ratios. These primers are
labeled “G” in Table S2.
After completion of our experiments, we discovered
that primer sets for two candidate genes, CYP2D6 and
NTAN1, amplified off-target segments of DNA (see notes
at the end of Additional file 2, Table S2). Because of pos-
sible conflation of genotyping and mRNA expression
data with a highly homologous pseudogene, CYP2D6 was
dropped from the list of “successfully analyzed” genes. By
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PCR products for AEI analysis. Analysis of primer sets
for all the other candidate genes using NCBI’s PRIMER-
BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/
)a n d / o rU C S C sIn-silico PCR (http://genome.ucsc.edu/
cgi-bin/hgPcr?command=start) programs predicted
amplification of only the intended target sequences.
cDNA synthesis
Complementary DNA was generated from 5 μg total RNA
in 20 μl reaction mixes using SuperScript
® III First Strand
kits (Invitrogen, Carlsbad, CA, USA) and 1 μlo f5 0μM
oligo(dT)20 primers, according to the directions of the
manufacturer. cDNA reaction mixes were diluted 2x with
DNAase- and RNAase-free water (Sigma; final volume
40 μl) and stored at -20 °C until use.
Screening brain samples for expression of target mRNAs
To obtain meaningful and reproducible AEI ratios, it is
essential that the RNA samples contain a sufficient num-
ber of candidate gene mRNA molecules. Our previous
experience suggests that a minimum of about 1,000
mRNA molecules is required to obtain stable AEI ratios
for many genes, an estimate consistent with a recently
published study [48]. To determine the appropriate brain
section for assessing AEI of candidate genes, PCR ampli-
fication was first carried out using cDNA derived from
purified prefrontal cortex RNA. Reaction mixes (20 μl
total volume) included: 1 μl cDNA (prepared as described
above), 0.5 μΜ (total) forward and reverse PCR primers,
0.8 mM dNTP mix, 0.5 Units rTaq (Takara), and 1x PCR
buffer (Takara). The amplification conditions comprised:
1x [94°C for 5 min], 28-30 cycles of [i) denaturation:
94°C for 30 sec; ii) annealing: 50-65 °C for 45 sec and iii)
elongation: 72°C for 30 sec], followed by a final elonga-
tion [72°C for 5 min] and short-term storage at 4°C or
long-term storage at -20°C.
For genes that generated sufficient PCR products to
produce strong, single bands on polyacrylamide gels
(minimum 50 ng/band after 30 cycles from 5 μla l i q u o t
of PCR reaction mix), prefrontal cortical RNA was used
for AEI analyses. For genes that did not yield sufficient
PCR products (less than 50 ng/band after 30 cycles
from 5 μl aliquot of PCR reaction mix), PCR products
from 2 to 3 independent cDNA synthesis reactions were
pooled or RNA isolated from other brain regions was
used as starting material. A list of the brain regions
used for AEI analysis for each gene can be found in
Additional file, Table S5. [Note: Assuming a PCR ampli-
fication efficiency of 2 and calculating backwards, 50 ng/
band = 200 ng total PCR product obtained after 30
cycles can be estimated to derive from approximately
1,800 molecules of mRNA.]
PCR amplification of genomic and cDNA segments
containing mSNPs
Segments of gDNA or cDNA containing mSNPs were
PCR-amplified using 5’-phosphorylated oligonucleotide
primers flanking the marker SNP. Gene-specific primer
pairs were designed to generate PCR products 66 - 100 bp
in length, with mSNPs located approximately in the cen-
ter. An upper limit of 100 bp was chosen to ensure that
mSNPs would be contained within 76 bp sequencing
reads beginning from either end of the PCR product. The
sequences of the gene-specific PCR primers are listed in
Additional file 2, Table S2. PCR reactions mixes and
amplification conditions are the same as those listed
above. To minimize the total number of PCR amplifica-
tions, we used only genomic and cDNA templates from
brain samples heterozygous for the mSNP for any particu-
lar candidate gene. A list of the number of brain samples
heterozygous for the mSNP for each candidate gene is
provided in Additional file 2, Table S5.
Following amplification, 5 μla l i q u o t so ft h e2 0μl
reaction mixes were resolved by electrophoresis on 15%
polyacrylamide gels and amounts of PCR products of
the predicted size quantified using the Molecular Ima-
ger
®XGel Doc XR+ System X with Quantity One
® 1-D
Analysis Software (Bio-Rad Laboratories). Approximately
equal amounts of PCR products derived from each can-
didate gene from a single brain sample were combined
and purified using QIAEXII, according to the directions
of the manufacturer (Qiagen, Valencia, CA, USA). Fol-
lowing resuspension in 40 μl distilled water, the
amounts of the pooled PCR products were quantified
using a Nanodrop Spectrophotometer (Thermo, Inc). In
all, 2 × 52 sets of pooled PCR products were prepared,
two sets (i.e., one gDNA-derived and one cDNA-
derived) for each of the brains in our collection.
Design and ligation of index-adapters
Fifty-two double-stranded index-adapters were synthesized
by Sangon Biotech (Shanghai). Each adapter contained a
five-base pair index linked to Illumina adapter sequences.
The five-base pair index sequences were designed follow-
ing Craig DW et al. [68], with identical nucleotides at the
1
st and 5
th positions to provide redundancy. A list of the
index sequences and corresponding sample numbers can
be found in Additional file 2, Table S3. As shown in Addi-
tional file 1, Figure S1, one strand of each index-adapter
contained an additional unpaired T residue at the 3’-end,
while the second strand was phosphorylated at the 5’-end
to facilitate ligation to the gene-specific PCR products.
The 2 × 52 sets of pooled PCR products (1.5 μg each)
were independently ligated to 52 sets of indexed Illumina
adaptors (3 μg each) using T4 DNA ligase (New England
Biolabs) at 16 °C overnight and then heated at 65 °C to
Xu et al. BMC Genomics 2011, 12:518
http://www.biomedcentral.com/1471-2164/12/518
Page 15 of 19inactivate the ligase. All of the ligation products were
then combined into 2x one tube (i.e., one for gDNA-
derived PCR products and one for cDNA-derived PCR
products) and purified and concentrated using QIAEXII
beads. The pooled ligation products were resolved by
electrophoresis on 3% agarose gels. DNA fragments in
the 150 to 220 bp range were extracted from the gels
using MiniElute Gel Extraction Kits (Qiagen).
Final steps in DNA sample preparation
To prepare the DNA fragments for sequencing, the ligated
gDNA- and cDNA-derived DNAs were independently
PCR-amplified using Illumina Primers 1.1 and 1.2 and
Phusion DNA polymerase (Finnzymes Oy). The PCR pro-
ducts were resolved by electrophoresis on 15% polyacryla-
mide gels and DNAs of the appropriate size extracted
using QIAquick Gel Extraction Kits (Qiagen). The concen-
tration and purity of the DNAs were accessed spectropho-
tometrially (First run: gDNA sample = 55.8 ng/μl; A260/
A280 ratio = 1.85; cDNA sample: 52.3 ng/μl; A260/A280
ratio = 1.89; second run: gDNA sample = 38.2 ng/μl; A260/
A280 r a t i o=1 . 9 1 ;c D N As a m p l e=5 1 . 4n g / μl; A260/A280
ratio = 1.91). A summary of the number of independent
samples (tubes) required for each step in the preparation
of DNA samples for sequencing in provided in Table 1.
Illumina sequencing
DNAs were prepared for sequencing on an Illumina Gen-
ome Analyzer 2.0 as described in the Single Read Cluster
Generation Kit (v3) and SBS Sequencing Kit (v3) User
Guides. Sequencing was carried out in the Laboratory of
Epigenetics, Institutes of Biomedical Sciences, Fudan
University. For Illumina assay-2, two flowcell lanes were
used for sequencing gDNA-derived PCR products and
five flowcell lanes for cDNA-derived PCR products. The
average yield was 7.54 × 10
6 independent sequencing
reads/lane, for a total of 52.8 × 10
6 independent reads.
The distribution of read lengths is shown in Additional
file 1, Figure S3(a).
Data analysis
As outlined in Additional file 1, Figure S2, sequencing
d a t af r o mt h eI l l u m i n aG e n o m eA n a l y z e r2 . 0w a s
matched to a custom sequence library using BLAST
2.2.25 (NCBI). The library comprised all possible combi-
nations of indices and candidate gene sequences (52
indices × 74 genes × 2 insert directions = 7,696 reference
sequences). Each sequencing read was transferred to a
folder corresponding to its top match and sequences
within each folder were aligned using MUSCLE 3.86 [69].
The SNP loci was then identified and the accuracy of the
read classifications and alignments confirmed by compar-
ing 20 bp sequences upstream and downstream from the
mSNP. The number of each mSNP allele was tabulated
and AEI ratios calculated using the mSNP allele assign-
ments (numerator and denominator) listed in Additional
file 2, Table S1.
Verification
Reproducibility of AEI measurements were evaluated by
linear regression analysis of log2AEI ratios obtained in
independent DNA-sequencing-based assays. For selected
genes, AEI ratios were also determined using SNaP-
shot
®-based AEI assays, and the closes results evaluated
by regression analysis. Representative examples of
regression analysis are shown in Additional file 1, Figure
S7. [Note: using regression analysis to compare replicate
samples works well for log2AEI distributions that span a
large range of values (negative to positive), but is not
very informative for log2AEI distributions that span a
small range of values. In addition, AEI ratios produced
by low-frequency variants replicate poorly, when small
numbers of samples are compared.]
Additional material
Additional file 1: Supplementary figures S1 - S7. Supplemental figures
related to our next-generation DNA sequencing-based AEI assay Figure
S1 - Preparation of samples for DNA sequencing. This diagram shows
molecular details involved in preparing DNA samples for sequencing
using the Illumina Genome Analyzer 2.0. Figure S2 - Flow diagram for
sorting DNA sequence reads. This figure outlines the steps carried out
by a computer program developed in- house for the calculation of AEI
ratios using data produced by Illumina sequencing. Figure S3 -
Percentage usable sequences. (a) Histogram of sequencing read
lengths. Approximately 85% of the sequences were 76 bp in length
following 76 sequencing cycles. (b) Among approximately 52.8 × 10
6
sequencing reads, 30% failed to meet match criteria in the BLAST step
and were discarded. Another 3% were discarded due to missing
sequence data for the marker SNP. Finally, 7% of the reads yielded
sequences containing only one of the two mSNP alleles (reflecting
genotyping errors or mistaken genotype imputation for the mSNP in
some samples), yielding approximately 31.7 × 10
6 reads suitable for
calculating AEI ratios. Figure S4 - Distribution of sequencing read
numbers used for the calculation of gDNA- and cDNA-based AEI
ratios. Histograms showing the distribution of (a) 13.2 × 10
6 gDNA reads
and (b) 18.5 × 10
6 cDNA reads (mSNP M-allele + m-allele) among the 70
candidate genes in this study. (Data from Additional file 2, Table S5)
Figure S5 - Distribution of non-corrected gDNA-based AEI ratios (a)
Distribution of experimentally determined gDNA AEI ratios. The ideal AEI
ratio for heterozygous samples = 1. (b) Regression analysis show that
there is no correlation between sequencing read number and calculated
gDNA ratios. Figure S6 - Error analysis (a) Plot of gDNA log2AEI ratios
vs number of sequencing reads with super-imposed plot of the
theoretical binominal sampling distribution (red trace), which was
calculated based upon the assumption that the M- and m-alleles of the
mSNP occur at equal frequency (0.5) in gDNA isolated from individuals
who are heterozygous for the mSNP. (b) Definition of experimental error
(E) based upon the distribution of [gDNA log2AEI ratio, sequence read
number] data points. The two horizontal lines are drawn at the same
distance above and below the X-axis, passing through the Y-axis at E
and -E, respectively. The vertical line denoted “X (reads)” forms the left
side of a rectangle that contains the data point with the highest
sequencing read in the experiment. When the horizontal lines are
adjusted so that the rectangle contains 95% of the data points with
sequencing reads greater than X, the values log2E and - log2E represent
the maximal ±log2 experimental errors of the measurement with 95%
confidence. When the horizontal lines are adjusted so that the rectangle
Xu et al. BMC Genomics 2011, 12:518
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Page 16 of 19contains 99% of the data points with sequencing reads greater than X,
the new values of + log2E and - log2E represent the maximum ± log2
experimental errors at 99% with confidence. (c) Empirically determined
correlations between experimental error (E) and sequencing reads. A
custom computer program was used to calculate correlations between
sequencing read number (X) and ± log2E at 95% and 99% confidence
levels. Figure S7 - Examples of correlations between independent
AEI assays. Representative linear regression analyses for 15 candidate
genes are grouped by level of statistical significance (P) for the
correlation.
Additional file 2: Supplementary tables S1 - S6. Detailed information
concerning our candidate neuropsychiatric disorder genes, PCR and
sequencing primers, experimental error and measured AEI ratios. Table
S1 - Neuropsychiatric disorder candidate genes. Table S2 - PCR
primer sequences. Table S3 - Index sequences. Table S4 -
Estimation of Experimental Error. Table S5 - Data for AEI ratio
measurements (Illumina Assay-2) Table S6 - SNPs within PCR primer
binding sites.
Additional file 3: Correction factors for AEI ratios and criteria for
the presence or absence of AEI in individual samples. A discussion of
factors that influence the measurement of genomic DNA AEI ratios and
criteria for assessing whether individual samples show allele-specific
differences in mRNA expression.
Additional file 4: Modeling population distributions of log2AEI
ratios. A brief outline of our method for modeling AEI ratios, including a
description of the modeling of log2AEI population distributions for GAB2,
GNB1L and DISC1.
Additional file 5: GAB2, GNB1L and DISC1: AEI measurements and
modeling. A discussion of inferences drawn from the modeling of GAB2,
GNB1L and DISC1 in the context of previously published studies on the
regulation of these genes.
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